Regulatory

A complete guide to Health Canada's pre-market guidance for machine learning-enabled medical devices (MLMD), published April 2026, covering predetermined change control plans (PCCP), data quality requirements, bias mitigation, lifecycle risk management, mandatory digital submissions, terms and conditions enforcement, and how Canada's approach compares to FDA and EU AI Act requirements.

How single-use medical device reprocessing saves hospitals $495.5 million, cuts CO2 emissions by 125 million pounds, and drives circular economy adoption in healthcare — based on 2025 AMDR industry data, peer-reviewed lifecycle assessments, Cardinal Health and Stryker sustainability programs, EU MDR remanufacturing regulations, and the regulatory framework governing reprocessed devices.

A practical guide to the most common notified body technical file deficiencies under EU MDR — clinical data gaps, disjointed risk management, incomplete equivalence claims, weak PMS integration — plus how Implementing Regulation (EU) 2026/977 changes NB assessment timelines and what manufacturers must do to prepare for conformity assessment review.

A data-driven analysis of FDA medical device warning letter trends from 2024 through early 2026, covering the most common violations (CAPA, design controls, complaint handling), QMSR enforcement shifts since February 2026, notable enforcement actions against Beta Bionics, Abbott, Medline, and Philips, and practical compliance strategies for medical device manufacturers.

How medical device sponsors can comply with FDA Diversity Action Plan requirements under FDORA sections 3601–3602, including enrollment goal setting by race, ethnicity, sex, and age group; device-specific considerations for IDE submissions; waiver criteria; and practical strategies for representative enrollment in device clinical investigations.

How to test AI-enabled medical devices for algorithmic bias across demographic subgroups, validate fairness using statistical methods, document bias analysis for FDA 510(k) and EU MDR submissions, and implement ongoing post-market monitoring — based on FDA AI-enabled device TPLC draft guidance, EU AI Act high-risk requirements, and 2026 regulatory expectations.

How to build a medical device cybersecurity incident response plan covering FDA 21 CFR 806 reporting, EU MDR vigilance obligations, CISA 72-hour notification, containment and eradication procedures, patient safety assessment, and coordination with ISAOs — based on the MITRE/FDA playbook, HPH sector guidance, and 2026 regulatory requirements.

How to write medical device design verification test protocols covering scope, acceptance criteria, test methods, sample size justification, pass/fail criteria, and result documentation — aligned with FDA design control requirements, EU MDR technical documentation expectations, ISO 13485 Clause 7.3.7, and the FDA recommended content format for non-clinical bench testing reports.

How the Department of Justice's record $6.8 billion False Claims Act enforcement in FY2025 impacts medical device companies — National Fraud Enforcement Division, Health Care Fraud Data Fusion Center using AI analytics, West Coast Strike Force, Anti-Kickback Statute compliance, whistleblower qui tam risks, and what manufacturers, distributors, and executives must do to reduce exposure in the most aggressive healthcare fraud enforcement environment in US history.

How much medical device clinical trials cost in 2026 — per-patient costs, site fees, CRO budgets, IDE preparation, monitoring, and total budget ranges from $300K early feasibility to $20M+ pivotal studies, with cost-saving strategies for 510(k), De Novo, and PMA pathways.

How to determine what human factors information to include in FDA medical device marketing submissions — three risk-based HF submission categories, critical task identification, use-related risk analysis, validation testing requirements, and documentation structure under the FDA's draft guidance on content of human factors information.

How to collect, validate, and submit Patient Preference Information (PPI) for medical device regulatory submissions under FDA's March 2026 final guidance — expanded scope to 510(k), IDE, and Breakthrough Device submissions, study design methods, benefit-risk assessment integration, and alignment with EU MDR/IVDR post-market follow-up principles.

Comprehensive guide to the EU's new Breakthrough Device (BtX) framework under MDCG 2025-9 and the EMA pilot program launching Q2 2026. Covers eligibility criteria, application process, benefits for manufacturers, comparison with the FDA Breakthrough Device Program, and what this means for IVD companies.

Detailed analysis of MedTech Europe's May 2026 position paper on the proposed MDR/IVDR revision. Covers breakthrough/orphan pathways, cybersecurity, AI integration, IVDR-specific concerns, and what manufacturers need to know about the coming legislative process.

Breaking down the FDA's May 2026 one-day inspection pilot that uses AI (Elsa) to target low-risk facilities. Covers how facilities are selected, what to expect during a screening inspection, how it differs from standard inspections, and what medical device manufacturers must do to stay ready.

The FDA's April 2026 real-time clinical trials initiative uses AI and cloud computing to monitor trial data as it is generated. This guide explains how the program works, the Paradigm Health platform, implications for medical device clinical investigations, and what sponsors must prepare to participate.

A complete guide to Commission Implementing Regulation (EU) 2026/977, published May 4, 2026, which sets uniform quality management and procedural requirements for Notified Bodies conducting conformity assessments under the MDR and IVDR. Covers maximum timelines, clock-stop rules, quotation transparency, re-certification procedures, and what manufacturers need to know.

A practical guide to the April 2026 MDCG updates affecting every EU medical device and IVD manufacturer. Covers MDCG 2021-24 Rev.1 classification guidance changes, EMDN v3/2026 code updates (MDCG 2026-1, 2026-2, 2026-3, MDCG 2021-12 Rev.2), the Borderline and Classification Manual Version 5, and what manufacturers must do to stay compliant.

Practical guide to building the critical-task matrix for auto-injector and pen-injector human factors validation — task identification from URRA, needle shield removal, site selection, dose confirmation, hold time, misfire recovery, training decay, disposal, use-error root cause analysis, and FDA/IEC 62366 evidence expectations.

How the EPA's 2026 proposed rollback of ethylene oxide emissions standards affects medical device manufacturers, sterilization facilities, and supply chains — the 2024 rule, proposed changes, compliance timelines, and alternative sterilization strategies.